At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 228 enrolled
Drug / intervention
Abaloparatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men With Osteoporosis
In Brief
A Phase 3 clinical trial evaluating Abaloparatide and Placebo for Osteoporosis and 5 related conditions. Completed, enrolled 228 participants across 34 sites in 3 countries.
Detailed Summary
A 12-month study to measure the efficacy and safety of abaloparatide in men with osteoporosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Osteoporosis, Age-Related, Osteoporosis Localized to Spine, Age Related Osteoporosis, Osteoporosis Senile, Osteoporosis of Vertebrae
CountriesItaly, Poland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartMay 2018
Primary CompletionAug 2021
Study CompletionSep 2021
TodayJul 2026
First PostedApr 30, 2018
Enrollment StartMay 3, 2018
Primary CompletionAug 17, 2021
Study CompletionSep 8, 2021
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 8.2 years ago
Interventions
Abaloparatidedrug
Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
Placebodrug
Abaloparatide-matched placebo.